Overview

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Status:
RECRUITING

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

Phase:

PHASE1

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

3-aminopyridine-2-carboxaldehyde thiosemicarbazone
Magnetic Resonance Spectroscopy
Radiotherapy, Intensity-Modulated
Specimen Handling